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A B S T R A C T
We investigated the association of adherence to the Mediterranean diet and other risk factors for dyslipidemia in
HIV-infected Croatian patients during the first year of highly active antiretroviral therapy (HAART). Adherence to the
Mediterranean diet was determined by a 150-item questionnaire; a 0 to 9-point diet scale was created that stratified re-
spondents as having low adherence (<4 points) and moderate to high adherence ( 4 points). We interviewed 117 partici-
pants between May 2004 and June 2005 and abstracted their serum lipid measurements taken during the first year of
HAART. The values of total cholesterol, HDL-cholesterol, LDL-cholesterol and triglycerides increased most prominently
in the first 3 to 6 months after initiation of HAART (average increase at 3 months: 25% for total cholesterol, 22% for
LDL-cholesterol, 18% for HDL-cholesterol and 43% for triglycerides). A Mediterranean diet and physical activity had no
effect on serum lipids. The mean total cholesterol was higher in participants receiving a combination of a non-nucleoside
reverse transcriptase inhibitor and a protease inhibitor compared to participants receiving a combination of nucleoside
analogs with a non-nucleoside analog or a combination of nucleoside analogs and a protease inhibitor. Among individ-
ual drug treatments, indinavir/ritonavir had the most unfavorable lipid profile. We conclude that adherence to a Medi-
terranean diet does not influence serum lipid profiles during the first year of HAART.
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Introduction
Abnormalities in lipid metabolism have been reported
among patients infected with the human immunodefi-
ciency virus (HIV) even before the introduction of highly
active antiretroviral therapy (HAART)1–3. Elevated lev-
els of triglycerides and decreased total cholesterol and
HDL-cholesterol have been shown to be positively corre-
lated with the progression of HIV infection and have be-
come a common finding in AIDS1.
Results of cross-sectional and longitudinal studies re-
ported dyslipidemia in participants treated with all three
drug classes, including protease inhibitors (PI)4–9, nu-
cleoside reverse transcriptase inhibitors (NRTIs)10,11,
and non-nucleoside reverse transcriptase inhibitors
(NNRTI)11–15. Changes in lipid metabolism due to treat-
ment with these drugs include increases in total chole-
sterol6,9,16, high-density lipoprotein (HDL)-choleste-
rol17–21, low-density lipoprotein (LDL)-cholesterol16,22–24,
and triglycerides17,25.
We have previously reported that moderate to high
adherence to the Mediterranean diet was associated with
a lower risk of clinical lipohypertrophy in 136 Croatian
HIV-infected patients on HAART26. Non-smokers who at
least moderately adhered to the Mediterranean diet had
a lower risk of clinical lipoatrophy26. The purpose of this
study was to estimate the magnitude of lipid changes and
identify risk factors that influence lipid metabolism dur-
ing the first year of HAART. We were specifically inter-
ested in whether adherence to the Mediterranean diet
was associated with fewer lipid alterations in Croatian
patients.
423
Received for publication September 25, 2008
Patients and Methods
Study population
The present report includes 117 of 136 participants
from the study on the effect of the Mediterranean diet on
body shape changes during HAART because baseline
(prior to HAART) lipid measurements were not available
for 19 participants. We assessed body shape changes and
adherence to the Mediterranean diet between May 2004
to June 2005. We abstracted data on lipids and other bio-
chemical measurements from the electronic database of
the Outpatient HIV/AIDS Department at the University
Hospital for Infectious Diseases in Zagreb, Croatia which
provides centralized care for all HIV-infected patients27.
We included measurements taken from July 1997 to May
2005.
Inclusion and exclusion criteria
Male or female outpatients were eligible for study if
they were older than 18 years of age, had documented
HIV infection, had received HAART for at least one year,
and had serum lipid measurements before start of HAART
available. We excluded participants if they had uncon-
trolled opportunistic infections or disseminated malig-
nancies or were pregnant or breast feeding.
Dietary assessment
We assessed adherence to the Mediterranean diet
through a 150-item, interviewer-administered semi-
-quantitative food-frequency questionnaire provided by
Antonia Trichopoulou28 and translated into Croatian.
For each of the items in the questionnaire, subjects re-
ported frequency of consumption and portion size, and
the average monthly intake was divided into daily por-
tions. To assist in accurate determination of portions, we
provided 76 photographs depicting typical portion sizes.
We divided items into 12 food groups: potatoes, vegeta-
bles, legumes, fruit and nuts, dairy products, cereals,
meat, poultry, fish, olive oil, eggs and alcoholic beverages.
For each participant, intake of each of the indicated
groups in grams per day and total energy intake were cal-
culated. Potatoes were added to the cereal group and
poultry was combined with meat to form single catego-
ries. We also calculated the ratio of monounsaturated
fats to saturated fats. We used the 10-point Mediterra-
nean diet scale developed by Trichopoulou A. et al28 to
determine dietary influence. For each subject, a value of
0 or 1 was assigned for each of the nine components of
the Mediterranean diet instrument. We used the gen-
der-specific median consumption value as the cutoff
point in each food category. For the six beneficial catego-
ries (vegetable, legumes, fruits and nuts, cereal, fish and
monounsaturated fat to saturated fat ratio) we assigned
a value of 0 to subjects who consumed an amount below
the median. For the two animal protein categories (meat
plus poultry, and dairy), a value of 1 was assigned to sub-
jects who consumed an amount below the median for
each of these categories. For ethanol consumption, we as-
signed a value of 1 to men who consumed 10 grams per
day and to women who consumed 5 grams per day. The
Mediterranean diet score ranged from 0 to 9, with higher
scores indicating greater adherence to the traditional
Mediterranean diet. Because of the small number of par-
ticipants in our study, we dichotomized the Mediterra-
nean diet score into below the median (<4 points, indi-
cating low adherence to the Mediterranean diet) and at
or above the median (4 points, indicating moderate to
high adherence to the Mediterranean diet).
Energy expenditure
Energy expenditure was assessed through the seven-
-item International Physical Activity Questionnaire29,
translated into Croatian. This questionnaire measures
self-reported physical activity. The information collected
on the time spent walking, in moderate intensity and vig-
orous activity was used to estimate total weekly physical
activity. We estimated physical activity using a weighted
energy coefficient, the metabolic equivalent (MET). One
MET-minute score is defined as the number of calories
that a 60 kg person spends during calm sitting. For any
kinds of walking we used 3.3 METs, for moderate physi-
cal activity we used 4 METs, and for vigorous physical ac-
tivity we used 8 METs. We multiplied the MET value by
the time spending on each of these activities. We ex-
pressed total physical activity was in minutes per week
and recalculated it in hours per days.
Biologic measures
We measured plasma total cholesterol, HDL-choles-
terol, LDL-cholesterol and triglycerides by standard en-
zymatic techniques and HIV RNA level using the Am-
plicor Monitor RT-PCR assay (Roche Molecular Systems)
with lower limit detection of 50 or 400 copies/mL. We
performed CD4 lymphocyte counts by flow cytometry.
Follow up of participants
Participants generally reported for evaluation six
times over the first year of treatment with HAART, and
they had blood samples drawn at each visit by nursing
staff. The first visit was the baseline assessment before
initiation of therapy. Follow-up visits were at one month
(range 15 to 60 days), three months (range 61 to 150
days), six months (range, 151 to 240 days), nine months
(range, 241 to 330 days) and 12 months (range, 331 to
422 days).
Variables
The outcome variables were serum total cholesterol,
HDL-cholesterol, LDL-cholesterol and triglycerides,
which we assessed at every visit. The principal predictor
variable was adherence to the Mediterranean diet. We
modeled antiretroviral treatment as a time-dependent
variable. We recorded the use of each individual anti-
retroviral drug and antiretroviral class of drugs. Other
variables included in the crude or multivariate analyses
were age, gender, HIV risk behavior (heterosexual sex,
men having sex with men, or other [injection drug use,
hemophiliacs and unknown]), year of starting HAART,
history of AIDS-defining illnesses, presence of lipody-
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strophy, baseline hemoglobin, plasma viral load, CD4 cell
count, smoking status, energy expenditure, olive oil con-
sumption and alcohol intake. We dichotomized plasma
viral load at 400 copies/mL, baseline CD4 count at 50 or
200 cells per mm3, and baseline hemoglobin at the me-
dian (>123 g/L). We categorized olive oil intake as yes
and no, and compared moderate alcohol consumption
(10 g/day) to no intake (<10 g/day) and no smoking to
current/former smoking. We assessed clinical lipoatro-
phy and lipohypertrophy subjectively by participants and
physicians as previously described30 and expressed total
physical activity in hours per day dichotomized at the
median (>9.3 MET/h/d).
Statistical analysis
We describe our data with frequencies, medians, and
interquartile ranges. The McNemar test was used to
compare dichotomized lipid measurements at baseline
with those at 12 months. We assessed the correlation be-
tween hemoglobin and total cholesterol with Pearson’s
correlation coefficient. We log-transformed the values of
triglycerides for analysis due to non-normal distribution
and examined changes in mean total cholesterol, HDL-
-cholesterol, LDL-cholesterol and triglycerides graphi-
cally over time. The crude analyses included measure-
ments of lipids over time against one independent vari-
able. In the multivariate model we added the principal
predictor (adherence to the Mediterranean diet over ti-
me) and those variables with a level of p0.25 in crude
analyses. We performed repeated measures of analysis of
variance using the unstructured covariance matrix pa-
rameterization and explored the validity of models by
graphical presentation of the residuals. We compared the
results over time as the percentage of difference between
categories with corresponding 95% confidence intervals
and used Proc Mixed, SAS, version 9.13 (SAS Institute,
Cary, NC, U S A) for our analyses.
Results
Characteristics of the study population
A total of 117 participants (males: 96, 82%) were in-
cluded in the study. There were 696 measures of total
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TABLE 1
BASELINE CHARACTERISTIC OF 117 HIV PARTICIPANTS AT THE FIRST LIPIDS MEASUREMENT
Characteristics N or median Percentage or interquartile range
Age, years 38.8 32.5–46.2
Male gender 96 82.1
HIV transmission
MSM 52 44.4
Heterosexual 44 37.6
Intravenous drug use 12 10.3
Blood/blood product recipient 3 2.6
Unknown 6 5.1
Smoking (current or former) 79 68
Year of beginning treatment
1999 36 30.8
2000–2001 35 29.9
2000 46 39.3
AIDS diagnosis 56 47.9
Viral load (copies/mL) 209 000 74 604–640 000
CD4 count (cells/mm3) 85 30–201
Weight (kg) 76 64–83
Body Mass Index 23.9 21.6–26.1
Hemoglobin g/L 123 110–138
Lipids (mmol/L)
Cholesterol 4.1 3.6–4.8
HDL-cholesterol 0.9 0.6–1.1
LDL-cholesterol 2.5 2.0–3.2
Triglycerides 1.6 1.2–2.0
Initial HAART
NNRTI + PI 14 12
Two NRTIs + NNRTI 30 25.6
Two NRTIs + PI 73 62.4
NNRTI – nonnucleoside reverse transcriptase inhibitor, PI – protease inhibitor, NRTIs – nucleoside reverse transcriptase inhibitors,
MSM– men who have sex with men, HAART– highly active antiretroviral therapy
cholesterol, 676 measures of HDL-cholesterol, 613 mea-
sures of LDL-cholesterol, and 696 measures of triglycer-
ides. The main demographic and clinical characteristics
are presented on Table 1. The values of total cholesterol,
HDL-cholesterol, LDL-cholesterol and triglycerides in-
creased most prominently in the first 3 to 6 months after
initiation of HAART (average increase at 3 months: 25%
for total cholesterol, 22% for LDL-cholesterol, 18% for
HDL-cholesterol and 43% for triglycerides). At baseline
we observed a total cholesterol level >5 mmol/L in 21
(18%) participants, an HDL-cholesterol level >1 mmol/L
in 33 (28%), an LDL-cholesterol level >3 mmol/L in 33
(28%), and a triglyceride level >1.7 mmol/L in 52 (44%)
participants. After 12 month of HAART treatment, we
found total cholesterol >5 mmol/L in 74 (64%) partici-
pants (p<0.001), HDL-cholesterol >1 mmol/L in 54 (47%)
(p<0.002), LDL-cholesterol >3mmol/L in 65 (56%) (p<0.001),
and triglycerides >1.7 mmol/L in 74 (64%) (p<0.001).
We assessed that 78 (67%) of participants adhered
moderately or highly to the Mediterranean diet. Partici-
pants with adherence to the Mediterranean diet did not
differ from those without adherence with respect to the
following baseline total cholesterol, HDL-cholesterol,
LDL-cholesterol, or triglycerides. Among the 117 HIV-in-
fected participants, 73 (62%) were exposed to the combi-
nation of two nucleoside reverse transcriptase inhibitors
(NRTI) plus a protease inhibitor (PI), 30 (26%) to the
combination of two NRTIs plus a non-nucleoside reverse
transcriptase inhibitor (NNRTI), and 14 (12%) exposed
to the combination of one NNRTI plus one PI.
Dietary assessments and energy expenditure
There was no statistically significant difference be-
tween serum lipid level and adherence to the Mediterra-
nean diet based on dichotomized Mediterranean diet
score. The mean difference in total cholesterol, HDL-cho-
lesterol, LDL-cholesterol and triglycerides between those
who did not adhere to those who adhered to the Mediter-
ranean diet was 0.1% (95% CI –1.5 to 1.6; p=0.975), 1.5%
(95% CI –1.0 to 3.7; p=0.778), –3.9% (95% CI –6.6 to –1.5;
p=0.460), –11.9% (95% CI –19.1 to –6.4; p=0.256) re-
spectively. Olive oil consumption was also not associated
with decreased lipids level. Seventy-four (63%) partici-
pants reported low-to-moderate (median 13.5 g/day) olive
oil intake. Moderate ethanol intake had no effect on se-
rum total cholesterol, LDL-cholesterol, and triglyceride
level. Participants who consumed moderate amounts of
ethanol (10 g/d) had less HDL-cholesterol than those
with less or no ethanol intake (Table 2). There was no
statistically significant difference between serum lipid
level and energy intake.
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TABLE 2
RELATIONSHIP BETWEEN PATIENTS CHARACTERISTICS AND CHANGE IN SERUM TOTAL CHOLESTEROL, HDL-CHOLESTEROL,
LDL-CHOLESTEROL LEVEL IN 117 PARTICIPANTS, MULTIVARIATE ANALYSIS
Characteristics
Total cholesterol HDL-cholesterol LDL-cholesterol
Estimate 95% CI Estimate 95% CI Estimate 95% CI
Age >39, years –9.2% a* –9.4% –9.0% –13.0% a* –13.4% –12.6%
Gender, male 2.8% –1.0% 6.2% 15.8%* 12.0% 19.0% –6.4%a –14.2% 0.2%
HIV transmission category
Heterosexuals vs. other –9.6%* –13.0% –6.7% –10.9% –16.1% –6.5%
Homosexuals vs. other –7.6% –9.8% –5.7% –13.3%* 17.4% –9.9%
Aids defining diagnosis –2,3% –2.5% 2.1%
Lipoatrophy 9.0% 8.2% 9.9%
Lipohipertrophy 10.3% 9.5% 11.3%
Viral load (>400 copies/mL) 5.1%* 4.6% 5.7%
CD4 count >200 cells/mm3 –2.5% –2.8% –2.1% –6.8% –7.0% –6.7%
CD4 count >50 cells/mm3 –14.1%* –16.8% –11.8%
Hemoglobin >123 g/L –10.2%* –10.7% –9.6% –12.7%* –13.1% –12.1%
Mediterranean diet –0.9% –2.2% –0.2% 0.7% –1.5% 2.5% –6.6% –9.0% –4.6%
Ethanol 10 g/d vs. <10 g/d 18.2%* 14.1% 23.3%
Smoking –6.8%* –8.3% –5.4% –11.3%* –14.5% –8.7%
Treatment
NNRTI+PI vs. two NRTIs+NNRTI –10.5%* –10.9% 10.0% 5.6% 1.8% 10.6% –1.9% –4.1% 0.9%
NNRTI+PI vs. two NRTIs+PI –8.8%* –10.0% –7,5% 0.7% –4.1% 7.1% –3.4% –6.3% 0.4%
a Variable had time interaction and results at twelve month are presented.
* Parameters were statistically significant (P<0.05).
NNRTI – nonnucleoside reverse transcriptase inhibitor, NRTIs – nucleoside reverse transcriptase inhibitors, PI – protease inhibitor,
CI – confidence interval
The characteristics +/– the percentage gives the value of the variable without the given characteristics.
Factors related to lipid changes
In the multivariate analysis, we found that age >39
years, heterosexual transmission, baseline hemoglobin
>123 g/L, smoking or former smoking, treatment with
NNRTI plus PI, and use of stavudine and indinavir/
ritonavir were associated with higher levels of choles-
terol (Table 2 and 3). Viral load >400 copies/mL was
associated with lower levels of total cholesterol (Table 2).
Hemoglobin levels were inversely correlated with total
cholesterol levels; i.e. participants with lower levels of
hemoglobin had lower level of total cholesterol (p<.001).
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TABLE 3
RELATIONSHIP BETWEEN ANTIRETROVIRAL DRUGS AND CHANGES IN SERUM TOTAL CHOLESTEROL, HDL-CHOLESTEROL,
LDL-CHOLESTEROL LEVEL, MULTIVARIATE ANALYSIS
Drug
Total cholesterola HDL-cholesterolb LDL-cholesterolc
Estimate 95% CI Estimate 95% CI Estimate 95% CI
Zidovudine 13.4%d * 12.8% 14.0% –2.2% –2.8% –1.5% 12.1%d * 11.7% 12.6%
Stavudine –6.8%d * –7.5% –6.0% 6.1% 5.5% 6.9% –9.4%* –10.5% –8.2%
Lamivudine 1.6% 0.2% 3.2% –8.7% –14.4% –3.1% 1.7% –1.3% 4.2%
Efavirenz –1.7% –1.8% –1.6% 2.2% 1.1% 3.6% 2.0%d 1.1% 3.0%
Indinavir 0.4% –0.5% 1.4% 35.0%d* 27.0% 45.8% –0.8%d –2.5% 1.3%
Ritonavir/Indinavir –22.1%d * –23.6% –20.3% 16.9%* 10.2% 25.7% –8.3% –10.7% –5.3%
Lopinavir/Ritonavir 3.4% –0.7% 6.5% –10.4% –13.8% –6.2% 7.9% 3.2% 14.1%
aAdjusted for time, age, gender, HIV transmission, viral load, CD4 lymphocytes, hemoglobin, smoking, Mediterranean diet and one
particular drug.
b Adjusted for time, gender, AIDS diagnosis, lipoatrophy, lipohypertrophy, CD4 count >50 cells/mm3, ethanol consumption,
Mediterranean diet and one particular drug.
c Adjusted for time, age, gender, HIV transmission, CD4 count >200 cells/mm3, hemoglobin, smoking, Mediterranean diet and one
particular drug.
d Variable had time interaction. The results at 12 months are presented.
* Parameters were statistically significant (P<0.05).
The characteristics +/– the percentage gives the value of the variable without the given characteristics.
TABLE 4
RELATIONSHIP BETWEEN VARIABLES AND PARTICULAR ANTIRETROVIRAL DRUGS AND CHANGE IN SERUM TRIGLYCERIDE LEVEL,
MULTIVARIATE ANALYSIS
Variablesa Estimate 95% Confidence interval
Gender male –11.8% –25.2% 2.0%
CD4 count >200 cells/mm3 19.8% 12.0% 33.1%
Mediterranean diet –9.4% –16.2% –4.5%
Treatment
NNRTI+PI vs. two NRTIs+NNRTI –26.7% –28.6% 25.7%
two NRTIs+PI vs. two NRTIs+NNRTI –26.9%* –36.1% –20.4%
Antiretroviral drugsb
Zidovudine 27.0%c * 23.1% 33.2%
Stavudine –19.0%c –19.4% –18.5%
Lamivudine –14.7% –26.7% –6.1%
Efavirenz 17.6% 13.4% 24.2%
Indinavir 43.5%* 26.3% 78.1%
Indinavir/Ritonavir –42.7% c * –44.3% –40.3%
Lopinavir/ritonavir –6.7% –13.2% 4.5%
a Included in the model: time, gender, CD4 count >200 cells/mm3, Mediterranean diet and type of antiretroviral treatment.
b Included in the model time, gender, CD4 count >200 cells/mm3, Mediterranean diet an the particular drug.
c Variable had time interaction. The result from the measurement at twelve months is shown.
* Parameters were statistically significant (P<0.05).
NNRTI – non-nucleoside reverse transcriptase inhibitors, NRTIs – nucleoside reverse transcriptase inhibitors, PI – protease inhibitor.
The characteristics +/– the percentage gives the value of the variable without the given characteristics.
Higher levels of HDL-cholesterol were associated with a
baseline CD4 cell count >50 cells/mm3, while male gen-
der, use of indinavir, and indinavir/ritonavir were associ-
ated with lower levels HDL-cholesterol (Table 2 and 3).
Factors related to levels of LDL-cholesterol were similar
to those found for total cholesterol (Table 2 and 3). In
crude analyses, triglyceride levels were significantly hi-
gher in participants treated with the combination of two
NRTIs plus PI compared to participants treated with two
NRTIs plus one NNRTI (–27.1%, 95% CI –35.9– 20.1%,
p<0.005). Treatment with indinavir/ritonavir (–40.4%,
95% CI –43.1–36.3%, p<0.001) increased the level of tri-
glycerides most among the various treatments.
In the multivariate analysis, participants treated with
two NRTIs plus PI combination had higher triglycerides
levels than participants treated with two NRTIs plus
NNRTI (Table 4). The use of indinavir/ritonavir was as-
sociated with highest levels of triglycerides (Table 4).
Discussion
We found no association between plasma lipid chan-
ges during the first year of HAART and adherence to the
Mediterranean diet. This is similar to the non-HIV in-
fected population where adherence to the Mediterranean
diet does not correlated well with levels of serum lipids31.
It is believed that the protective effects of the Mediterra-
nean diet are not related to serum concentrations of to-
tal, LDL, or HDL-cholesterol but rather to changes ob-
served in plasma fatty acids32. Controlled feeding studies
have shown that the Mediterranean diet, where mono-
unsaturated and polyunsaturated intake was relatively
high, largely from olive oil, did reduce LDL-cholesterol
and triglycerides and increased HDL-cholesterol33. In a
randomized trial for management of hypercholesterol-
emia in patients on PI-containing HAART, pravastatin
and dietary advice lowered cholesterol levels, whereas di-
etary advice alone had no effect on lipid levels34.
We also did not find an association between adherence
to the Mediterranean diet and energy intake or a correla-
tion between plasma lipids and energy intake. There also
appeared to be no beneficial effect of physical activity on
lipid levels. Recent clinical trials have not demonstrated
a consistent change in lipid levels in patients undertak-
ing aerobic exercise35,36. Earlier clinical trials showed a
beneficial effect of exercise on lipids levels in HIV in-
fected persons treated with HAART37–39. We found, as
others have, a significant increase in lipids after initia-
tion of HAART9,17,18,21,40,41. This increase was most prom-
inent during the first three months of therapy17,21,41.
The most frequent NNRTI plus PI combinations used
in our study were lopinavir/ritonavir plus efavirenz or
indinavir plus efavirenz. Similarly to other larger multi-
center cohort studies, participants treated with a NNRTI
plus PI combinations had more pronounced elevations of
total cholesterol compared to patients taking two NRTIs
plus NNRTI and two NRTIs plus PI14,42.
The two most commonly used NRTIs in our study
were stavudine and zidovudine. Treatment with stavu-
dine was associated with increased total cholesterol com-
pared with zidovudine and this has also been previously
described11,43. In earlier studies stavudine was rarely
changed, because PIs were believed to cause lipid eleva-
tions44,45. Because of the association with lipoatrophy,
stavudine is today seldom used as first-line nucleoside
treatment in developed countries46, but it is still used in
developing countries with limited choices of antiretro-
viral drugs46–48.
We also confirmed that older age is associated with
higher levels of total cholesterol and LDL cholesterol
(Table 2)11,14,49,50. Participants with lower levels of base-
line hemoglobin (<123 g/L) were more likely to have
lower levels of total cholesterol and LDL-cholesterol.
This might be a reflection of the more severe HIV disease
in participants with lower hemoglobin levels. Also, base-
line low levels of CD4 cells (<50 cells/mm3) in serum
were associated with lower HDL-cholesterol concentra-
tions and this has also been previously reported14,51,52. A
detectable viral load of >400 copies/mL of HIV RNA was
most probably a result of non-adherence, so it is not sur-
prising that it was associated with lower levels of total
cholesterol as suggested by Friis-Moller et al.14.
Prevalence of smoking or former smoking was high
(67%; current smokers, 49%) in our study population.
However, current smoking was lower in our study popu-
lation compared to findings from Italy (60%)53, Swiss
(57%)54, and Norway (54.5%)55. Smoking or former smo-
king was associated with higher levels of total cholesterol
and LDL-cholesterol. Cigarette smoking is known to in-
crease total cholesterol, LDL-cholesterol and triglycer-
ides, while decreasing HDL-cholesterol56. It has been
shown that cigarette smoking induces oxidative modifi-
cation of plasma LDL and this may subsequently pro-
mote the atherogenic process57.
Limitations of the study should be noted. Patients are
instructed to come to routine visits at our outpatient
HIV/AIDS Center in a fasting state. However, this is not
always the case and there were no records in our data-
base on the fasting status. This might have affected some
of our results, particularly the levels of LDL-cholesterol
and triglycerides. There was also a relatively large time
span (from July 1997 to May 2004) when HAART was
initiated. Since the interview about adherence to the
Mediterranean diet took place from May 2004 to June
2005 some of the patients might have changed their diet
since they started of HAART. However, our findings of
the relationship between various HAART regimens and
individual antiretroviral drugs are very consistent with
previous reports.
This study provides important information on lipid
changes and factors associated with their increase dur-
ing the first year of HAART in Croatian patients. It
should be noted that the benefits of Mediterranean diet
in terms of survival are beyond the changes in lipids.
Further studies are needed to evaluate whether adher-
ence to the Mediterranean diet of HIV infected patients
treated with HAART is beneficial in terms of prolonged
survival.
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DISLIPIDEMIJA I PRIDR@AVANJE MEDITERANSKOJ PREHRANI U BOLESNIKA
IZ HRVATSKE ZA VRIJEME PRVE GODINE LIJE^ENJA VRLO DJELOTVORNOM
ANTIRETROVIRUSNOM TERAPIJOM
S A @ E T A K
Istra`ili smo pridr`avanje mediteranskoj prehrani i druge rizi~ne ~imbenike koji su povezani s dislipidemijom u
bolesnika zara`enih HIV-om iz Hrvatske za vrijeme prve godine lije~enja vrlo djelotvornom antiretrovirusnom tera-
pijom (HAART). Pridr`avanje mediteranskoj prehrani odre|eno je upitnikom od 150 pitanja; u~injena je skala od 0 do 9
stupnjeva po kojoj su ispitanici podijeljeni na one koji se slabo pridr`avaju (<4 stupnja) i one koji se umjereno do visoko
pridr`avaju (4 stupnja). Razgovarali smo sa sto i sedamnaest sudionika od svibnja 2004 do lipnja 2005. godine, a
njihova mjerenja lipida izdvojena su iz elektronske baze podataka. Vrijednosti ukupnog kolesterola, HDL-kolesterola,
LDL-kolesterola i triglicerida najzna~ajnije su porasli u prvih tri do {est mjeseci nakon otpo~injanja lije~enja HAART-om
(prosje~no pove}anje u prva 3 mjeseca je: 25% za ukupni kolesterol, 22% za LDL-kolesterol, 18% za HDL-kolesterol i
43% za trigliceride). Mediteranska prehrana i fizi~ka aktivnost nisu utjecale na razine lipida u serumu. Srednje vri-
jednosti ukupnog kolesterola bile su vi{e u sudionika koji su lije~eni kombinacijom nenukleozidnog inhibitora reverzne
transkripraze i inhibitora proteaze ako se usporedi sa sudionicima koji su lije~eni nukleozidnim analozima sa nenu-
kleozidnim analozima ili kombinacijom nukleozidnih analoga i inhibitora proteaze. Izme|u pojedinih lijekova, lije~enje
indinavirom/ritonavirom imalo je najnepovoljniji profil lipida.
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